Acadia Pharmaceuticals Inc.
Records under this name other than the patents Acadia Pharmaceuticals Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 47 patents it holds.
Back to Acadia Pharmaceuticals Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,370,755 | Compositions of Trofinetide Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 11,866,406 | Compositions of Trofinetide Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 10,653,629 | Single layer oral dose of neuro-attenuating ketamine Surrendered on reissue Surrendered on reissue Feb 24, 2026 · From the USPTO record | Surrendered on reissue | Surrendered on reissue Feb 24, 2026 | From the USPTO record |
| US 7,713,995 | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Term ended Term ended Dec 27, 2025 · From the USPTO record | Term ended | Term ended Dec 27, 2025 | From the USPTO record |
| US 7,659,285 | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Term ended Term ended Nov 19, 2025 · From the USPTO record | Term ended | Term ended Nov 19, 2025 | From the USPTO record |
| US 7,923,564 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms Term ended Ended no later than Sep 26, 2025 · From the USPTO record | Term ended | Ended no later than Sep 26, 2025 | From the USPTO record |
| US 8,236,960 | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms Term ended Ended no later than Sep 26, 2025 · From the USPTO record | Term ended | Ended no later than Sep 26, 2025 | From the USPTO record |
| US 9,670,209 | Muscarinic Agonists Lapsed on the fee record Ended Jun 6, 2025 · High confidence | Lapsed on the fee record | Ended Jun 6, 2025 | High confidence |
| US 7,994,193 | Selective Serotonin 2A/2C Receptor Inverse Agonists as Therapeutics for Neurodegenerative Diseases Term ended Term ended Jan 15, 2024 · High confidence | Term ended | Term ended Jan 15, 2024 | High confidence |
| US 8,008,323 | Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases Term ended Ended no later than Jan 15, 2024 · From the USPTO record | Term ended | Ended no later than Jan 15, 2024 | From the USPTO record |